Trial intelligence / Profile preview

Tezepelumab in inadequately controlled asthma

NCT03688074Phase 2Completed

Sponsor
AstraZeneca
Start
Nov 2018
Primary completion
Nov 2020
Modality
Monoclonal Antibodies
Countries
5
01

Overview

A Phase 2 trial of tezepelumab in asthma, sponsored by AstraZeneca. Started Nov 2018; status: completed.

02

Drugs

03

Conditions

asthma

Beyond the preview

Go deeper on NCT03688074.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03688074.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call